In January 2025, the MIB project (Marseille Immunology Biocluster) joined CISAM by establishing its startup studio on site.
Marseille Immunology Biocluster (MIB) is a project aiming to strengthen France’s influence in healthcare. Led by Aix-Marseille University and involving over 20 partners (Big Pharma, biotech, research entities, hospitals, technology transfer entities, local authorities …) it is backed by a €96 million budget under the France 2030 government initiative to advance immunotherapy drug development.
Located in the heart of Marseille, a city with over 40 years of immunology research history, MIB’s mission is to foster and expand cooperation among all players in shaping the future of immunology at national, European, and international levels.
As both a biocluster and a catalyst for innovation, MIB brings together leading scientists, clinicians, and industry experts to accelerate the development of new antibody-based therapies for patients and to push the boundaries of healthcare innovation.
Researchers, hospital practitioners, industry players, investors, students and public authorities will benefit from services such as technology platforms, an immunology startup studio and innovation support for SMEs to accelerate translational immunology research. The focus will be on four therapeutic areas: oncology, infectious diseases, autoimmune disorders, and inflammatory diseases.
This pragmatic approach, which aims to develop innovative treatments, novel diagnosis tools and MEDTECH will establish Marseille as a global hub for immunology research and enhance France’s scientific standing on the international stage.
